MedTrace Logo

An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

NCT05663853 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 137

Last updated 2024-06-11

No results posted yet for this study

Summary

All males and females between 18-70 years of age regardless of their race and ethnicity with a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), and Relapse Remitting Multiple Sclerosis (RRMS) are invited to participate in this Observational study being conducted across four sites in the US. Since this is an observational study no medication/drug or treatment will be given to the participants. The investigator will be collecting information about the participant's MS disease, its progression, current medications, radiographic scans, and blood samples. This will help the investigator evaluate the biomarkers and new treatment options to better understand the MS disease process.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting
  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Secondary Progressive

Sponsors & Collaborators

  • LAPIX Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Shin, MD,FANA · Prof of Neurology MedStar Georgetown University Hospital

  • Sylvia Klineova, MD,MS · Assistant Prof of Neurology Icahn School of Medicine at Mt Sinai

  • Shiv Saidha, MD,MRCPI · Prof of Neurology, Johns Hopkins Hospital, Baltimore MD

  • Robert Bermel, MD,MBA · Director Mellen Center for Multiple Sclerosis, Cleveland Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-28
Primary Completion
2024-04-30
Completion
2024-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05663853 on ClinicalTrials.gov